Antibodies that bind IL-18 and methods of inhibiting IL-18 activity

US7767207B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Tariq Ghayer · Holliston, US
• Richard W. Dixon · Jefferson, US
• Michael Roguska · Cambridge, US
• Michael White · Framingham, US
• Boris Labkovsky · Framingham, US
• Jochen G. Salfeld · North Grafton, US
• Alexander Robert Duncan · Buckley, GB
• Simon Mark Brocklehurst · Fulbourn, GB
• John A. Mankovich · Andover, US
• Celia Patricia Shorrock · Saint-Égrève, FR
• Julia Elizabeth Thompson · Maidstone, GB
• Simon Nicholas Lennard · Stowmarket, GB

Key dates

• Filing date: Feb 9, 2001
• Grant date: Aug 3, 2010
• Expiry date: Feb 9, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.